1802220-02-5

Usage

Uses

Used in Oncology:
TPX-0005 is used as an ROS1 inhibitor for the treatment of cancer. It has demonstrated activity against various resistance mutations, including G2032R, D2033N, L2026M, S1986F/Y, and L1951R. Additionally, it has shown activity against kinases involved in bypass signaling, such as focal adhesion kinase, SRC proto-oncogene, and non-receptor tyrosine kinase. TPX-0005 is particularly useful in overcoming resistance mutations and improving treatment outcomes for patients with ROS1-positive tumors.

Upstream product

• 347-54-6 5-fluoro-2-hydroxybenzaldehyde 
• 64248-64-2 2,5-difluorobenzonitrile 
• 1802222-53-2 (R)-2-(1-aminoethyl)-4-fluorophenol hydrochloride 
• 1224944-77-7 5-chloropyrazolo[1,5-a]pyrimidine-3-carboxylic acid ethyl ester 

Relevant academic research and scientific papers

Macrocyclic compounds

The invention discloses compounds represented by formula (I), or pharmaceutically acceptable salts thereof, and also relates to a preparation method of the compounds represented by formula (I) or thepharmaceutically acceptable salts thereof, a medicinal composition containing the compounds represented by formula (I) or the pharmaceutically acceptable salts thereof, and a use of the compounds represented by formula (I) or the pharmaceutically acceptable salt thereof. R1 and R2 in the formula (I) are as defined in the present application.

CHIRAL DIARYL MACROCYCLES AND USES THEREOF

This disclosure relates to the use of certain diaryl macrocycle compounds, specifically (7S13R)-11-fluoro-7,13-dimethyl-6,7,13,14-tetrahydro-1,15-ethenopyrazolo[4,3-f][1,4,8,10]benzoxatriazacyclotridecin-4(5H)-one in the treatment of disease in mammals. T

DIARYL MACROCYCLE POLYMORPH

This disclosure relates to polymorphs of (7S,13R)-11-fluoro-7,13-dimethyl-6,7,13,14-tetrahydro-1,15-ethenopyrazolo[4,3-f][1,4,8,10]benzoxatriazacyclotridecin-4(5H)-one that are useful in the treatment of disease, such as cancer, in mammals. This disclosur

DIARYL MACROCYCLES AS MODULATORS OF PROTEIN KINASES

The present invention relates to certain diaryl macrocyclic compounds, pharmaceutical compositions containing them, and methods of using them, including methods for treating cancer, pain, neurological diseases, autoimmune diseases, and inflammation.